Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01543490 · ClinicalTrials.gov registry record · Phase 3
Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects
A Phase 3 study, sponsored by Sun Pharmaceutical Industries Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 558
- Enrollment target
NCT01543490 is a Phase 3 study that has completed, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 558 participants.
The verdict
NCT01543490, a Phase 3 study, has completed, sponsored by Sun Pharmaceutical Industries Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 558 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of subjects with active, symptomatic Blepharitis.
Interventions
- OTHER Vehicle
- DRUG ISV-305
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 558 participants |
| Start Date | 2018-03-30 |
| Est. Completion | 2020-02-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01543490
The ClinicalTrials.gov registry entry for NCT01543490 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 558 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT01543490 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01543490 about?
NCT01543490 is a clinical study titled "Comparative Study to Evaluate ISV-305 Compared to Vehicle in Blepharitis Subjects". The purpose of this study is to evaluate the clinical efficacy and safety of ISV-305 (Dexamethasone in DuraSite® 2) compared to Vehicle in the treatment of subjects with active, symptomatic Blepharitis.
What is the current status of trial NCT01543490?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 558 participants. The study started on 2018-03-30. Estimated completion is 2020-02-04.
What interventions are being tested in trial NCT01543490?
The interventions under investigation include: Vehicle (OTHER), ISV-305 (DRUG).
Who is sponsoring clinical trial NCT01543490?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.